Shibeikang Completes Nearly RMB 100 Million Series B Financing to Advance Metabolism-Differentiated Innovative Therapies in Cardiovascular and Respiratory Diseases

Recently, Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as “Shibeikang”) announced the completion of its Series B financing round, raising nearly RMB 100 million. This round was exclusively strategically invested by the listed company Chengda Pharmaceuticals Co., Ltd., and the proceeds will be primarily used forAccelerate the development of the R&D pipeline,Expand R&D laboratories and advance the international regulatory filing process for core products. Previously, in its early startup phase, Shibeikang also secured investments from industrial investors such as Fosun Pharma and Sichuan Venture Capital, as well as local investment institutions.

Shibeikang, established in 2015, is a differentiated new drug R&D enterprise based in China and oriented towards the global market. The company adheres toDriven by the dual engines of “urgent clinical needs” and “global innovation,” with a focus on therapeutic areas such as cardiovascular, cerebrovascular, and respiratory diseases, we have built an independent development system covering the entire drug R&D value chain, leveraging our proprietary AI-driven metabolic differentiation technology platform.。

The company’s R&D team possesses full-chain independent development capabilities, spanning bioinformatics, structural design, CMC, pharmacology and toxicology studies, patent research, clinical trials, and regulatory submissions. The team was selected as a top-tier innovation and entrepreneurship team under Chengdu’s “Rongpiao Plan” in 2021 and as an entrepreneurial team under the “Tianfu Emei Plan” in 2022. Thirty-two percent of the team members hold master’s or doctoral degrees, with an average of over 20 years of experience in drug development and management.

On the long journey of innovative drug development, unclear drug metabolism characteristics and low clinical translation rates are common pain points. The core competitiveness of BIOMEDICAL stems from its independently constructed“A-MetaForge™” Maichuang Intelligent Repair AI Metabolic Differentiation Platform。

By integrating cross-species metabolic data with AI algorithmic models, the platform enables precise, differential analysis of drug metabolic properties, uncovering metabolic features that traditional models fail to capture. Through multi-dimensional modeling, it accurately identifies clinical metabolic liabilities and guides structural optimization, significantly enhancing R&D efficiency and success rates from early drug discovery to clinical translation, thereby continuously delivering innovative drugs that truly address unmet clinical needs.

Leveraging this platform, BIOMEDICAL has strategically laid out multiple innovative product pipelines in the fields of cardiovascular, cerebrovascular, and respiratory diseases, with several candidates currently in various stages of clinical development.

In response to the "four highs and one high prevalence" characteristics of cardiovascular and cerebrovascular diseases, BIOMEDICAL has laid out five Class 1 new drugs. Supported by its AI-driven metabolic differentiation platform, the company has built a full-cycle disease solution covering diagnosis, prevention, and treatment through multi-target coverage and multi-mechanism synergy. In the field of respiratory diseases, the company has also developed two Class 1 new drugs, both of which have entered clinical trials.

This round of financing goes beyond financial support; it represents a significant integration of strategic resources between both parties.

Chengda Pharmaceuticals Co., Ltd., as an enterprise with international standards in pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and CDMO services, possesses a mature global quality system and compliance capabilities. BIOMEDICAL, leveraging its differentiated R&D pipeline and accumulated innovative technologies, demonstrates significant advantages in early-stage drug discovery and clinical development.

Through this collaboration, Chengda Pharmaceuticals Co., Ltd. will leverage its extensive expertise in active pharmaceutical ingredient (API) development, GMP manufacturing, and international registration to provide comprehensive, systematic empowerment for BIOMEDICAL’s global expansion of multiple product pipelines, thereby accelerating the internationalization of its products. In terms of API supply and manufacturing processes, relying on its leading downstream API production technologies, mature operational system aligned with international quality standards, and capabilities in developing high-value-added APIs, Chengda Pharmaceuticals will ensure a stable, compliant, and efficient supply of APIs and intermediates for BIOMEDICAL’s innovative drug pipeline during both clinical and commercial stages, guaranteeing from the source that drug quality meets international norms. Regarding international drug registration and GMP compliance, Chengda Pharmaceuticals’ rich practical experience will provide critical support for BIOMEDICAL’s market access in major global pharmaceutical markets such as the United States and Europe, effectively reducing registration risks and expediting the regulatory approval process.

By organically integrating capital and industrial empowerment, the two parties will form a strategic alliance centered on “R&D + Manufacturing + Internationalization,” achieving full-cycle synergy from early-stage research to commercial production.

Looking to the future, BIOMEDICAL will prioritize the efficient advancement of its clinical-stage pipeline in the short term, accelerating the market launch of innovative drugs developed with a metabolism-differentiation approach that demonstrate clear efficacy and safety. In the long term, the company will deepen its integrated “prevention-diagnosis-treatment” strategy, build a cardiovascular and cerebrovascular ecosystem, continuously enhance its source innovation capabilities, and ultimately deliver First-in-Class new drugs with global patents available for out-licensing.

Regarding this round of financing,Tan Shaojun, Founder and Chairman of BIOMEDICALHe stated, “We are deeply grateful to the investors for their recognition and trust in Shibeikang. This financing round marks a critical step forward as the company advances into the globalization and commercialization phases. Chengda Pharmaceuticals Co., Ltd. not only possesses global CDMO capabilities that align closely with our international strategic planning, but also enables us to systematically address production and supply chain bottlenecks associated with product internationalization. Furthermore, the financial support from Chengda Pharmaceuticals will provide robust assurance for our R&D innovation, empowering us to deepen our expertise in the fields of cardiovascular, cerebrovascular, and respiratory diseases. We will remain committed to clinical value-oriented development, accelerating the availability of innovative drugs with globally differentiated competitive advantages to benefit patients as soon as possible.”

Chengda Pharmaceuticalsstated: “Leveraging its globally leading R&D platform for metabolic differentiation and end-to-end innovative solutions for clinical translation, BIOMEDICAL has successfully accelerated the efficient clinical translation of multiple new drugs. We look forward to collaborating with BIOMEDICAL to explore innovative drug development, support the optimization of its product pipeline, expand clinical application scenarios, and advance its global expansion. Through this partnership, we will fully support BIOMEDICAL in reaching new heights of development, jointly creating greater value for the global healthcare industry.”

Chengdu Shibeikang Biomedical Technology Co., Ltd., established in 2015, is an R&D-focused enterprise rooted in China and oriented towards the global market, specializing in differentiated innovation in new drug development. Adhering to its mission of “Benefiting All People, Safeguarding Health,” the company upholds the values of “people-oriented, reform-driven, and innovation-first.” Guided by clinical needs and committed to a strategic positioning of improved and differentiated R&D, Shibeikang insists on innovation-driven development. It has established an AI-enabled, full-cycle R&D iteration platform for innovative drugs, spanning from early discovery to clinical translation. With a key focus on therapeutic areas such as cardiovascular, cerebrovascular, and respiratory diseases, the company is dedicated to becoming a world-class leader in differentiated new drug innovation, developing better medicines to benefit all people and provide enhanced protection for human health. For more details, please visit the official website at https://www.sbkswyy.cn/ or follow the WeChat official account “Shibeikang Biomedical.”

Chengda Pharmaceuticals Co., Ltd. was established in 1999. As a high-tech enterprise, it specializes in the research and development, production, and sales of pharmaceutical intermediates, chemical active pharmaceutical ingredients (APIs), and food and feed additives. The company was listed on the Shenzhen Stock Exchange in 2022 (Stock Code: 301201). Chengda Pharmaceuticals is one of the major global suppliers of L-carnitine series products. It is also committed to providing CDMO R&D and manufacturing services for key pharmaceutical intermediates and APIs to global pharmaceutical companies and medical R&D institutions during drug clinical trials and commercialization stages. Furthermore, the company engages in the R&D and registration of generic APIs and has strategically laid out its business in biological innovative drugs. Upholding the business philosophy of “Innovation Wins the Future, Integrity Reaches the World,” Chengda Pharmaceuticals is market-oriented, technology-centric, and innovation-driven, collaborating with industry leaders to build a global innovation chain. For more details, please visit the official website of Chengda Pharmaceuticals at https://www.chengdapharm.com or follow the “Chengda Pharmaceuticals” WeChat official account.